

E-PRA and E-PSM Circular RNA for Cancer Vaccine Research

Catalog Number:CVAC-ORNA-0455

DESCRIPTION	
Product Name	E-PRA and E-PSM Circular RNA for Cancer Vaccine Research
Gene Name	E-PRA and E-PSM
Source	In vitro transcribed mRNA was further circularized to make this product as a circular RNA.
Alternative names	Synthetic Peptides E-PRA And E-PSM Vaccine
SPECIFICATIONS	
Cap	
5'-UTR	5' -untranslated region derived from human alpha-globin RNA with an optimized Kozak sequence
ORF	E-PRA and E-PSM
3'-UTR	3' UTR comprising two sequence elements derived from the aminoterminal enhancer of split (AES) mRNA and the mitochondrial encoded 12S ribosomal RNA
Poly(A) Tail	
Modifications	N1-methyl-pseudouridine
Neutral Lipid	1,2-distearoyl-sn-glycero-3-phosphocholine (DSPC)
Cholesterol	Cholesterol
Ionizable Lipid	1,2-dimyristoyl-rac-glycero-3-methoxypolyethylene glycol-2000 (PEG2000-DMG)
PEG-lipid	Heptadecan-9-yl 8-((2-hydroxyethyl)(8-(nonyloxy)-8-oxooctyl)amino)octanoate)(SM-102)
Storage	-80 °C
Buffer	PBS, pH7.5
Cryoprotectant	Trehalose
BACKGROUND	
Gene Accession	
Gene Alias	Synthetic Peptides E-PRA And E-PSM Vaccine

antigens upregulated and expressed on the cell surfaces of certain tumor cell types. (NCIT_C67098).

Background

Description: A cancer vaccine consisting of E-PRA and E-PSM, two synthetic peptide analogs of PRAME (PReferential Antigen MELanoma) and PSMA (Prostate Specific Membrane Antigen), with potential immunostimulating activity. Upon direct administration into lymph nodes, synthetic peptides E-PRA and E-PSM vaccine may stimulate a cytotoxic T-lymphocyte (CTL) response against PRAME- and PSMA-expressing tumor cells. PRAME and PSMA are tumor-associated